Shijiazhuang Yiling Pharmaceutical (002603) Q2 2025 earnings summary

Executive summary

• Revenue for H1 2025 was ¥4.04 billion, down 12.26% year-over-year; net profit attributable to shareholders rose 26.03% to ¥669 million.

• Cash flow from operations surged 214.97% to ¥832 million; basic EPS increased 26.05% to ¥0.4002.

• The company will distribute a cash dividend of ¥3.00 per 10 shares, totaling ¥501 million.

Financial highlights

• Operating income: ¥4.04 billion (–12.26% YoY); net profit: ¥669 million (+26.03% YoY).

• Gross margin improved, with heart/cerebrovascular and respiratory products accounting for 71.4% of revenue.

• Cash and cash equivalents at period end: ¥1.04 billion; total assets: ¥13.9 billion (+4.36% from year-end).

• R&D investment: ¥399 million, 9.87% of revenue, above industry average.

Outlook and guidance

• Management focuses on product structure optimization, cost control, and digital transformation to support long-term growth.

• Continued investment in R&D and new product launches expected to drive future performance.